SAB Biotherapeutics
Quarterly Financials
| Values in thousands | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $114 |
Gross Profit | -765 | -822 | -778 | -671 |
EBITDA | 46,254 | -9,227 | -4,348 | -10,538 |
EBIT | 45,488 | -10,049 | -5,127 | -11,323 |
Net Income | 5,337 | -10,114 | -5,196 | -11,394 |
Net Change In Cash | 0 | 0 | 0 | 114 |
Free Cash Flow | -13,050 | -7,151 | -7,797 | -9,326 |
Cash | 29,424 | 3,692 | 5,640 | 8,897 |
Basic Shares | 77,863 | 9,294 | 9,292 | 9,262 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,322 | $2,239 | $23,904 | $60,876 |
Gross Profit | -3,470 | -1,506 | 20,612 | 59,222 |
EBITDA | -28,994 | -38,133 | -15,122 | -15,196 |
EBIT | -33,786 | -41,878 | -18,414 | -16,850 |
Net Income | -34,105 | -42,194 | -18,741 | -17,145 |
Net Change In Cash | 1,322 | 2,239 | 23,904 | 60,876 |
Cost of Revenue | -24,498 | 26,934 | ||
Free Cash Flow | -34,629 | -25,316 | -25,625 | -8,956 |
Cash | 8,897 | 56,566 | 15,046 | 33,206 |
Basic Shares | 9,262 | 5,521 | 4,352 | 2,734 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-09-30 | -$0.21 |
2025-06-30 | -$1.09 |
2025-03-31 | -$0.56 |
2024-12-31 | -$0.98 |
